Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21575845rdf:typepubmed:Citationlld:pubmed
pubmed-article:21575845lifeskim:mentionsumls-concept:C1527169lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C0005507lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C0029974lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C0733758lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C0577559lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:21575845lifeskim:mentionsumls-concept:C1708059lld:lifeskim
pubmed-article:21575845pubmed:dateCreated2011-5-17lld:pubmed
pubmed-article:21575845pubmed:abstractTextThis study assessed the ovarian stimulation characteristics of recombinant follitropin a filled by mass (rFSH-fbm) versus recombinant follitropin a filled by conventional bioassay (rFSH-bio) in the same egg donor patients. Eleven egg donors, who had two ovarian stimulation cycles for oocyte retrieval (total of 23 cycles), one with rFSH-bio (Gonal-f Multidose®) and the second one with rFSH-fbm (Gonal-f® RFF), were evaluated. The protocol of ovarian stimulation was exactly the same in both cycles, consisting of GnRH suppression (luteal phase) followed by exclusive stimulation with rFSH. Despite no differences in the number of days of rFSH treatment and in the total dosage of rFSH administered, the number of follicles >14 mm and the number of oocytes retrieved were significantly higher in the rFSH-fbm group (P = 0.01 and 0.04 respectively). The mean oestradiol peak values showed a trend in favour of rFSH-fbm (3123 versus 2405 pg/ml respectively). These results suggest that the consistency in dosing provided by follitropin a filled by mass as opposed to follitropin a filled by bioassay offers added value for the ovarian stimulation of oocyte donor patients.lld:pubmed
pubmed-article:21575845pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21575845pubmed:languageenglld:pubmed
pubmed-article:21575845pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21575845pubmed:statusPubMed-not-MEDLINElld:pubmed
pubmed-article:21575845pubmed:monthFeblld:pubmed
pubmed-article:21575845pubmed:issn1472-6491lld:pubmed
pubmed-article:21575845pubmed:authorpubmed-author:AriciAydinAlld:pubmed
pubmed-article:21575845pubmed:authorpubmed-author:PatrizioPasqu...lld:pubmed
pubmed-article:21575845pubmed:authorpubmed-author:MartinezGusta...lld:pubmed
pubmed-article:21575845pubmed:authorpubmed-author:SanguinetiFab...lld:pubmed
pubmed-article:21575845pubmed:authorpubmed-author:SepulvedaJose...lld:pubmed
pubmed-article:21575845pubmed:authorpubmed-author:DoreyJessicaJlld:pubmed
pubmed-article:21575845pubmed:copyrightInfoCopyright © 2011 Reproductive Healthcare Ltd. Published by Elsevier Ltd.. All rights reserved.lld:pubmed
pubmed-article:21575845pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21575845pubmed:volume22 Suppl 1lld:pubmed
pubmed-article:21575845pubmed:ownerNLMlld:pubmed
pubmed-article:21575845pubmed:authorsCompleteYlld:pubmed
pubmed-article:21575845pubmed:paginationS20-2lld:pubmed
pubmed-article:21575845pubmed:year2011lld:pubmed
pubmed-article:21575845pubmed:articleTitleA comparison between follitropin ? filled by mass and follitropin a filled by bioassay in the same egg donors.lld:pubmed
pubmed-article:21575845pubmed:affiliationYale University Fertility Center, Department of Obstetrics and Gynecology and Reproductive Sciences, New Haven, CT, USA.lld:pubmed
pubmed-article:21575845pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:21575845lld:pubmed